Suchergebnisse - "Buti, Maria"

PubPharm (14)

1

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

enthalten in: Gut | 2023

von Janssen, H. | Hou, J. | Asselah, T. | +16

2

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

enthalten in: The New England journal of medicine | 2022

von Yuen, M. | Lim, S. | Plesniak, R. | +132

CommentIn: N Engl J Med. 2022 Nov 24;387(21):1996-1998. - PMID 36346068

3

Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6

enthalten in: Journal of viral hepatitis | 2019

von Lawitz, E. | Gane, E. | Feld, J. | +56

4

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis : OMEGA-1

enthalten in: Hepatology (Baltimore, Md.) | 2019

von Zeuzem, S. | Bourgeois, S. | Greenbloom, S. | +19

5

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

enthalten in: Gastroenterology | 2018

von Esteban, R. | Pineda, J. | Calleja, J. | +19

CommentIn: Gastroenterology. 2018 Oct;155(4):969-971. - PMID 30201359

6

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B) : two randomised, phase 2, open-label trials

enthalten in: The lancet. Gastroenterology & hepatology | 2017

von Lawitz, E. | Buti, M. | Vierling, J. | +26

CommentIn: Lancet Gastroenterol Hepatol. 2017 Nov;2(11):771-772. - PMID 28802817

7

Short article : Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study

enthalten in: European journal of gastroenterology & hepatology | 2016

von Zeuzem, S. | Mantry, P. | Soriano, V. | +11

8

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease : a multicentre, open-label, randomised, phase 2 trial

enthalten in: The Lancet. Infectious diseases | 2016

von Manns, M. | Samuel, D. | Gane, E. | +23

CommentIn: Lancet Infect Dis. 2016 Jun;16(6):624-625. - PMID 26907737

9

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection

enthalten in: Journal of hepatology | 2016

von Zeuzem, S. | Hézode, C. | Bronowicki, J. | +23

10

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor : Final 24-Week Results From C-SALVAGE

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2016

von Buti, M. | Gordon, S. | Zuckerman, E. | +11